Sotrovimab News and Research

RSS

The challenges of Omicron

A new review published in sums up the position of Omicron as a potential threat to human health, especially in the context of controlling this pandemic.

25 Apr 2022

Antibody escape in SARS-CoV-2 Omicron spike protein

Researchers examined antibody escape and cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.

22 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

...

8 Apr 2022

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

Researchers described a case of co-infection with SARS-CoV-2 variants of concern, Delta and Omicron.

8 Apr 2022

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Researchers tested the efficacy of sotrovimab in non-hospitalized patients with SARS-CoV-2 infection.

7 Apr 2022

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

A new study presented the rapid profiling of a SARS-CoV-2 Delta-Omicron recombinant sequence from Europe.

6 Apr 2022

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Researchers investigated how monoclonal antibodies, S309 and AZD7442, reduced lung infection in mice infected with the SARS-CoV-2 new variant of concern Omicron's BA.1, BA.1.1, and BA.2 sublineages.

23 Mar 2022

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

Researchers reported a new monoclonal antibody, P2G3, which significantly neutralized the SARS-CoV-2 Omicron variant.

23 Mar 2022

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Researchers discussed patient features, treatment-associated process measures, and outcomes associated with early monoclonal antibody and antiviral therapy in high-risk pediatric patients infected with the SARS-CoV-2 Omicron variant.

22 Mar 2022

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Researchers reported an epitope with high potency and breadth and demonstrated that a therapeutic antibody directed at this site neutralizes all SARS-CoV-2 variants.

18 Mar 2022

Researchers evaluate predictors for mortality in hospitalized COVID-19 patients

Researchers identified independent factors associated with early and late deaths in hospitalized COVID-19 patients.

17 Mar 2022

The effects of anti-SARS-CoV-2 monoclonal antibodies on pregnant and postpartum women

Researchers examine the safety and efficacy of mAbs in pregnant and postpartum women with COVID-19.

16 Mar 2022

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Researchers conducted an in vitro analysis to assess the efficacy of monoclonal antibodies against the SARS-CoV-2 Omicron BA.2 and BA.1 variants.

14 Mar 2022

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

Researchers evaluated the effectiveness of regdanvimab on clinical outcomes in patients with mild to moderate COVID-19.

7 Mar 2022

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Researchers assess the efficacy of 8G3, a B-cell neutralizing antibody against SARS-CoV-2 variants, including the most recent Omicron variant.

3 Mar 2022